Literature DB >> 15146462

Molecular and functional analysis of SUMF1 mutations in multiple sulfatase deficiency.

Maria Pia Cosma1, Stefano Pepe, Giancarlo Parenti, Carmine Settembre, Ida Annunziata, Richard Wade-Martins, Carmela Di Domenico, Paola Di Natale, Anuj Mankad, Barbara Cox, Graziella Uziel, Grazia M S Mancini, Enrico Zammarchi, Maria Alice Donati, Wim J Kleijer, Mirella Filocamo, Romeo Carrozzo, Massimo Carella, Andrea Ballabio.   

Abstract

Multiple sulfatase deficiency (MSD) is a rare disorder characterized by impaired activity of all known sulfatases. The gene mutated in this disease is SUMF1, which encodes a protein involved in a post-translational modification at the catalytic site of all sulfatases that is necessary for their function. SUMF1 strongly enhances the activity of sulfatases when coexpressed with sulfatase in Cos-7 cells. We performed a mutational analysis of SUMF1 in 20 MSD patients of different ethnic origin. The clinical presentation of these patients was variable, ranging from severe neonatal forms to mild phenotypes showing mild neurological involvement. A total of 22 SUMF1 mutations were identified, including missense, nonsense, microdeletion, and splicing mutations. We expressed all missense mutations in culture to study their ability to enhance the activity of sulfatases. Of the predicted amino acid changes, 11 (p.R349W, p.R224W, p.L20F, p.A348P, p.S155P, p.C218Y, p.N259I, p.A279V, p.R349Q, p.C336R, p.A177P) resulted in severely impaired sulfatase-enhancing activity. Two (p.R345C and p.P266L) showed a high residual activity on some, but not all, of the nine sulfatases tested, suggesting that some SUMF1 mutations may have variable effects on the activity of each sulfatase. This study compares, for the first time, clinical, biochemical, and molecular data in MSD patients. Our results show lack of a direct correlation between the type of molecular defect and the severity of phenotype. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15146462     DOI: 10.1002/humu.20040

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  22 in total

1.  A general binding mechanism for all human sulfatases by the formylglycine-generating enzyme.

Authors:  Dirk Roeser; Andrea Preusser-Kunze; Bernhard Schmidt; Kathrin Gasow; Julia G Wittmann; Thomas Dierks; Kurt von Figura; Markus Georg Rudolph
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-20       Impact factor: 11.205

2.  SUMF1 mutations affecting stability and activity of formylglycine generating enzyme predict clinical outcome in multiple sulfatase deficiency.

Authors:  Lars Schlotawa; Eva Charlotte Ennemann; Karthikeyan Radhakrishnan; Bernhard Schmidt; Anupam Chakrapani; Hans-Jürgen Christen; Hugo Moser; Beat Steinmann; Thomas Dierks; Jutta Gärtner
Journal:  Eur J Hum Genet       Date:  2011-01-12       Impact factor: 4.246

Review 3.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

Review 4.  Pathology and current treatment of neurodegenerative sphingolipidoses.

Authors:  Matthias Eckhardt
Journal:  Neuromolecular Med       Date:  2010-08-22       Impact factor: 3.843

Review 5.  Heparan sulfate proteoglycans as key regulators of the mesenchymal niche of hematopoietic stem cells.

Authors:  Dulce Papy-Garcia; Patricia Albanese
Journal:  Glycoconj J       Date:  2017-06-02       Impact factor: 2.916

6.  Sulfatase modifying factor 1-mediated fibroblast growth factor signaling primes hematopoietic multilineage development.

Authors:  Mario Buono; Ilaria Visigalli; Roberta Bergamasco; Alessandra Biffi; Maria Pia Cosma
Journal:  J Exp Med       Date:  2010-07-19       Impact factor: 14.307

7.  Multiple sulfatase deficiency: clinical report and description of two novel mutations in a Brazilian patient.

Authors:  Osvaldo Alfonso Artigalás; Luiz Roberto da Silva; Maira Burin; Gregory M Pastores; Bai Zeng; Nívea Macedo; Ida Vanessa Doederlein Schwartz
Journal:  Metab Brain Dis       Date:  2009-08-21       Impact factor: 3.584

8.  Proprotein convertases process and thereby inactivate formylglycine-generating enzyme.

Authors:  Eva C Ennemann; Karthikeyan Radhakrishnan; Malaiyalam Mariappan; Michaela Wachs; Thomas H Pringle; Bernhard Schmidt; Thomas Dierks
Journal:  J Biol Chem       Date:  2013-01-03       Impact factor: 5.157

Review 9.  Neonatal manifestation of multiple sulfatase deficiency.

Authors:  Andreas Busche; Julia B Hennermann; Friederike Bürger; Hans Proquitté; Thomas Dierks; Annabel von Arnim-Baas; Denise Horn
Journal:  Eur J Pediatr       Date:  2008-12-10       Impact factor: 3.183

10.  Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder.

Authors:  Carmine Spampanato; Elvira De Leonibus; Paola Dama; Annagiusi Gargiulo; Alessandro Fraldi; Nicolina Cristina Sorrentino; Fabio Russo; Edoardo Nusco; Alberto Auricchio; Enrico M Surace; Andrea Ballabio
Journal:  Mol Ther       Date:  2011-02-15       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.